Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Other

Ortho-mcneil Pharmaceutical Corp.

Mds R&d (china) Co., Ltd.

Deodialsingh Guiadeen

Shankaran Kothandaraman

Sander G Mills

Lihu Yang

Alexander Pasternak

Changyou Zhou

Gabor Butora

Gregori J Morriello

Stephen D Goble

Christopher Richard Moyes

Richard Jiao

Joseph A Kozlowski

Younong Yu

Jian Liu

Ping Liu

Ronald M Kim

Jiaqiang Cai

Alejandro Crespo

Weiguo Quan

Xiaoxing Du

Cheng Tang

Rongqiang Liu

Mark J Macielag

Hao Wu

Wensheng Yu

John S Debenham

Ying-Duo Gao

Brian M Andresen

Liping Wang

Christopher Joseph Sinz

Rajan Anand

Xiaolei Gao

Christina B Madsen-Duggan

Chundao Yang

Shilan Liu

Dahai Wang

Vincent Colandrea

Sobhana Babu Boga

Todd C Henninger

Oleg B Selyutin

Hongjian Wang

Eugene B Grant

Abdul-Basit Alhassan

Byron Dubois

Joshua G McCoy

Arto D Krikorian

Byron Gabriel Dubois

Christopher J Sinz

Jyhshing Wang

The present invention concerns a compound of formula I or a pharmaceutically acceptable salt thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier. 

Inhibitors of HIF prolyl hydroxylase

The present invention concerns compounds of formula I or pharmaceutically acceptable salts thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier. 

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or pharmaceutically acceptable salts thereof. Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders. 

BTK inhibitors

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders. 

Substituted benzamides and substituted pyridinecarboxamides as Btk inhibitors

The present invention is directed to methods for treating, preventing, ameliorating, controlling or reducing the risk of an inflammatory or immunoregulatory disorder or disease, which method comprises the administration to a patient of an effective amount of the compound of formula I: (wherein R, R, R, R, R, R, R, R, R, R, X, n and the dashed line are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.

Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity

The present invention is directed to compounds of the formula I: I(wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n and the dashed line are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2 

Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity

6-O-carbamate-11,12-lacto-ketolide antimicrobials

Growing community of inventors

Chesterfield, NJ, United States of America

Deodialsingh Guiadeen